Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"We do expect it to be available soon Tecovirimat. And CDC is currently developing an expanded access IND protocol to help facilitate the use of this product as a treatment for monkeypox as well," the CDC's Brett Petersen told doctors at the AMA webinar.
According to federal data, nearly 2,000 patients diagnosed with monkeypox have been treated with TPOXX so far, nearly all of them men. Only 24 women have been confirmed to have received TPOXX to treat monkeypox infections.
Ten of the patients in the study reported a complete resolution of their monkeypox lesions one week after starting treatment. The majority of the patients took TPOXX for 14 days. However, the study did not include a control group, limiting the researchers’ ability to measure effectiveness.
it's written on the wall........approved
winner$$$$$$$$
Update 09/14:
Dr. Fauci confirmed that TPOXX is currently undergoing phase-3 trials imminently. It’s just a matter of time until we get the approval by the FDA and then others will follow.
Moderna's bioRXiv article just out: Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
$SIGA It’s a great time to scoop up bargain stocks$$$$$$$$$$$$$$$$
$MRNA It’s a great time to scoop up bargain stocks
What's Moderna's Next Billion-Dollar Market- The Answer May Surprise You.
It's worth about $5 billion to $6 billion.
The company's flu candidate recently began a phase 3 study.
At the same time, Moderna predicts the annual coronavirus vaccine market in the U.S. alone may range from $5.2 billion to $13 billion. The exact number will depend on vaccine pricing and uptake among the population. But even at the low end, Moderna still has ensured itself one blockbuster product.
If all goes well with the flu candidate, Moderna may add a second blockbuster vaccine to its repertoire.
WINNER$$$$$$$$$$
https://www.fool.com/investing/2022/09/14/whats-modernas-next-billion-dollar-market/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Best Life: Using antivirals to treat monkeypox
“T-POXX is a medication [that] stops the replication, stops a duplication of the virus in your body. So, it’s very effective – if you can get one,” said
Winter.
https://www.actionnews5.com/2022/09/14/best-life-using-antivirals-treat-monkeypox/
TOKYO (Reuters) Moderna open to supplying COVID vaccines to China, CEO says
Moderna Inc has talked with the Chinese government about supplying COVID-19 vaccines, but no decision has been made, CEO Stephane Bancel said on Wednesday.
"We are open, we have the capacity" Bancel said about supplying its mRNA-based shots to the country, declining to say whether Moderna had submitted its vaccine for approval there.
There is about a 20% probability that a "problematic" variant of the virus could emerge this winter, Bancel said, adding it was not his base case scenario.
"We should just always be humble about biology," he said.
Bancel, speaking in Tokyo, said Moderna is considering building facilities in Japan to produce mRNA-derived products.
Japan on Monday approved vaccine boosters from Moderna and Pfizer Inc that target the Omicron variant of the coronavirus.
Moderna sued Pfizer Inc and its partner BioNTech SE last month for patent infringement in the development of the first COVID vaccine approved in the United States.
Moderna believed from the beginning of the outbreak that BioNTech was using its technology and patents, but decided to wait until the pandemic subsided to file suit, Bancel said.
Two Cases of Monkeypox-Associated Encephalomyelitis — Colorado and the District of Columbia, July–August 2022
Early Release / September 13, 2022
https://www.cdc.gov/mmwr/volumes/71/wr/mm7138e1.htm?s_cid=mm7138e1_w
Il CDC registra 646 nuovi casi di vaiolo delle scimmie negli Stati Uniti nelle ultime 24 ore mentre il conteggio dei casi sale a 22.630.
Spain : +103 (6,947)
France : +48 (3,833)
Belgium +18 (744)
France has an alarmingly high new female cases as they accounted for 12.9% of all new cases in the prior week.
Mexico records a big jump in monkeypox cases this week after the administration recorded 263 new cases for a total case count of 1,051.
This week we increased cases by about 33% compared to 55% last week.
$SIGA
This will be one of the strongest reasons for the FDA to approve TPOXX ASAP: Pregnant women infected by monkeypox have a 77% chance of fetal demise.
https://pubmed.ncbi.nlm.nih.gov/36096413/
First US death due to monkeypox confirmed in Los Angeles County
https://edition.cnn.com/2022/09/12/health/california-monkeypox-death/index.html
MINISTRY OF HEALTH, LABOUR AND WELFARE IN JAPAN APPROVES PARTIAL CHANGE TO A NEW DRUG AUTHORIZATION FOR MODERNA'S OMICRON-TARGETING BIVALENT BOOSTER COVID-19 VACCINE, MRNA-1273.214
https://investors.modernatx.com/news/news-details/2022/Ministry-Of-Health-Labour-and-Welfare-in-Japan-Approves-Partial-Change-to-a-New-Drug-Authorization-for-Modernas-Omicron-Targeting-Bivalent-Booster-COVID-19-Vaccine-mRNA-1273.214/default.aspx
The total number of shares in the company is now held by institutional investors and hedge funds, which account for 60.76 percent of the total.
https://beststocks.com/analysts-have-given-moderna-inc-nasdaqmrna-an/
don't forget to register! Webinar this Tuesday at 11 am focused on TPOXX! FDA, CDC and AMA!
https://www.ama-assn.org/about/events/what-physicians-need-know-about-tecovirimat-tpoxx-treatment-monkeypox
good for us$$$$$$$$$$$
looks good for next week, it's definitely safe and there's PLENTY of evidence to show it's effective. None to show it isn't that I'm aware of...and besides- risk is nothing in comparison to benefit. TPOXX currently qualifies and meets ALL OF THE FDA CRITERIA for EUA!
Monkeypox Has Potential to Cause Heart Problems
Patient in case study developed myocarditis following monkeypox infection
https://www.acc.org/About-ACC/Press-Releases/2022/09/01/15/31/Monkeypox-Has-Potential-to-Cause-Heart-Problems
$SIGA
news: U.S. Clinical Trial Evaluating Antiviral for Monkeypox Begins
NIH Trial Gathering Data on Tecovirimat (TPOXX)
September 9, 2022
https://www.niaid.nih.gov/news-events/us-clinical-trial-evaluating-antiviral-monkeypox-begins
The Lancet: Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat: He reported no significant adverse effects and the skin lesions healed rapidly.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01528-8/fulltext
$SIGA
In addition to a blistering rash and flu-like symptoms, the monkeypox virus could wreak havoc on your brain, new research reveals.
https://m.jpost.com/health-and-wellness/article-716738/amp
Brookline Capital Markets Sticks to Their Buy Rating for Moderna (MRNA)
https://www.tipranks.com/news/blurbs/brookline-capital-markets-sticks-to-their-buy-rating-for-moderna-mrna?utm_source=advfn.com&utm_medium=referral
Monkeypox update: FDA focuses on testing as cases continue to rise
https://healthexec.com/topics/healthcare-management/healthcare-policy/fda-issues-new-guidance-monkeypox-testing
US: Concerns Are Mounting Due to Escalating Monkeypox Outbreak
https://www.telesurenglish.net/news/US-Concerns-Are-Mounting-Due-to-Escalating-Monkeypox-Outbreak-20220908-0005.html
$SIGA alert... is manipulated!
mRNA-4157 Personalized Cancer Vaccine: The Phase 2 trial is fully enrolled and primary data are expected in 4Q 2022.
BIG NEWS OUT: MODERNA REVIEWS CLINICAL TRIAL PROGRAMS ACROSS PORTFOLIO AT 2022 R&D DAY
Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit
Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit
Moderna announces a new development candidate, mRNA-3139, for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder
Phase 3 clinical trial of RSV vaccine, mRNA-1345, has enrolled more than 24,000 of the 34,000-participant target
Phase 3 immunogenicity and safety study of flu vaccine, mRNA-1010, is fully enrolled; Company to pursue accelerated approval pathway in 2023
Company is on track to report data from its Phase 2 personalized cancer vaccine (PCV) study in 4Q 2022
Personalized Cancer Vaccine
Personalized cancer vaccines (PCV) target an individual patient's unique tumor mutations to selectively treat their cancer. Moderna's PCV program is being developed in collaboration with Merck.
mRNA-4157 is a PCV candidate designed to stimulate an immune response by boosting T cells, which are believed to be necessary for a curative cancer therapy. Moderna's Phase 2 clinical trial will determine if mRNA-4157 in combination with KEYTRUDA®, an approved cancer therapy, can improve recurrence-free survival (at 12 months) in patients with resected melanoma at high risk of recurrence, compared to KEYTRUDA alone. KEYTRUDA was selected as the comparator in the trial because it is considered the standard of care for high-risk melanoma patients.
The Phase 2 trial is fully enrolled and primary data are expected in 4Q 2022.
https://investors.modernatx.com/news/news-details/2022/Moderna-Reviews-Clinical-Trial-Programs-Across-Portfolio-at-2022-RD-Day/default.aspx
this is big!!! I've been waiting for this.........
https://sports.yahoo.com/us-lawmakers-set-quiz-health-182454743.html
Thank you Oregon !!!
"We're also encouraging providers to consider treatment with the TPOXX antiviral for people infected with monkeypox when they're first diagnosed to prevent complications, lessen symptoms and potentially decrease risk for transmission, regardless of disease severity (or risk of)."
— OR Health Authority (@OHAOregon) September 7, 2022
1 days to go! We will be hosting our R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022
$WINNER
Institutional Shares 29,023,148 - 39.74%
Insider Shares 28,016,560 - 38.37%
the value of being the only approved MP drug with multiple global clinical trials on deck, is much higher than where this is. There is zero reason for this share price EXCEPT manipulation. Why? Tutes not selling. What's the play? Something is up.
It's written on the wall over here- winner!!!!!!
There's an unexploded bomb in the next street.........
$SIGA
Global Monkeypox Treatment Market to Surpass US$ 258.6 Million by 2030 - Coherent Market Insights
https://www.prnewswire.co.uk/news-releases/global-monkeypox-treatment-market-to-surpass-us-258-6-million-by-2030-coherent-market-insights-802985410.html
TPOXX, a therapeutic originally approved for smallpox that is believed to be effective against monkeypox, will also be distributed under the $20 million contract.
https://www.foxnews.com/us/biden-administration-expanding-monkeypox-vaccine-distribution-20-million-amerisourcebergen-contract
Don't miss the White house update on Thursday 9/2 regards to the funding for monkeypox!
Moderna: Patient Investors Are Given Another Fantastic Buy Point On The Pullback
https://seekingalpha.com/article/4539015-moderna-another-fantastic-buy-point-on-pullback
$MRNA
New strain of monkeypox detected in the UK as officials urgently testing whether it’s a deadlier version
The strain which has just been discovered is thought to be the former more deadly version of the disease
https://www.thescottishsun.co.uk/health/9397167/new-monkeypox-detected-uk/
$SIGA
Baby hospitalized after testing positive for monkeypox
Officials said the infant in Washington State was exposed to the virus by an infected family member and is now being treated with an authorized anti-viral called TPOXX in a Seattle hospital.
https://www.avnblogfeed.com/2022/09/03/baby-hospitalized-after-testing-positive-for-monkeypox/